Broad spectrum antiviral drug inhibits a range of emerging coronaviruses
Submitted by Laura Sekela on Fri, 03/09/2018 - 09:46To date, no retroviral drug has been approved to treat coronavirus infections.
To date, no retroviral drug has been approved to treat coronavirus infections.
Based on incomplete and conflicting reporting, the Saudi Arabia Ministry of Health reported either 14 Middle East respiratory syndrome (MERS) cases in February or 16 cases.
A World Health Organization (WHO) update on Middle East respiratory syndrome (MERS) in Saudi Arabia revealed 25 laboratory-confirmed cases of MERS, including eight associated deaths in January 2018.
These recommendations focus on the hospital setting, the recommendations for personal protective equipment (PPE), source control, and environmental infection control measures are applicable to any healthcare setting.
The 20 cases of Middle East respiratory syndrome (MERS) infection are from 11 areas of the country.
Researchers used genetic sequence data to show that the Middle East respiratory syndrome (MERS) virus reaches a ‘dead end’ in humans.
Researchers believe they may be able to use transchromosomic cattle to rapidly produce human antibodies against other human pathogens as well, in as few as three months.
A Malaysian man was confirmed positive for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection after returning home from his umrah pilgrimage.
Saudi Arabia has reported an additional 18 cases of Middle East respiratory syndrome (MERS) infection since October 31.
Researchers analyzed the distribution of human outbreak cluster sizes and zoonotic introduction times and demonstrated that human outbreaks in the Arabian Peninsula are driven by seasonally varying zoonotic transfer of viruses from camels.